tbuckley/cabot-search huggingface dataset:
AB0878 Efficacy and Safety of Rumalaya Forte to Patients with Hand Osteoarthritis (HOA)
Authors: S. Patru, I.R. Marcu, D. Matei, A.C. Bighea
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Although Paracetamol and NSAIDs are commonly prescribed for the patients with osteoarthritis, gastrointestinal, hepatic and renal toxicity limit their usage. Herbal medicine is wide spread and presents a large source that might serve for development of novel drugs. Rumalaya Forte (RF) is one such poly herbal formulation prescribed to osteoarthritic patients for years. Several clinical studies have been undertaken with Rumalaya forte. <h3>Objectives</h3> This randomized, double-blinded, placebo controlled study tried to evaluate the clinical efficacy and safety of Rumalaya forte to patients suffering from HOA. <h3>Methods</h3> All the patients with clinical and radiological evidence of HOA were randomized into 2 groups of 20 patients each (Rumalaya forte and acetaminophen groups). Clinical evaluation was done at baseline and after the completion of six weeks, using a visual analogue scale for pain and morning stiffness and a hand function test with short administration time, the Moberg Picking-Up Test (MPUT). Were recorded all the adverse events. <h3>Results</h3> The treatment groups were comparable in terms of baseline characteristics. After 6 weeks of treatment RF decreased the pain by 31.7% and acetaminophen by 25.8%. Morning stiffness decreased by 37.2% in RF group and by 30.5% in the other treatment group. RF was significantly superior to acetaminophen in improving hand function (better times to 6 weeks MPUT, 12.3 sec.vs 14.8 sec.). There were no clinically significant adverse events in both groups. <h3>Conclusions</h3> RF was more effective as acetaminophen in improving hand osteoarthritis symptoms and increased joint mobility and strength to HOA patients. <h3>References</h3> Clinical evaluation of the efficacy of JT-2000* in the management of osteoarthritis: A double-blind placebo-controlled trial. Upadhyay, L., Tripathi, K. Medicine Update (2004): (11), 10, 31. Evaluation of the efficacy and safety of JT-2000* in Osteoarthritis: A randomized controlled clinical trial. Khare, K.D., Rahul Khare. Indian Journal of Clinical Practice (2004): (14), 10, 42. Evaluation and Comparative Clinical Efficacy and Safety of Rumalaya Forte in Patients Suffering from Osteoarthritis of the Knee. Nirbhay Srivastava, R Sadh, BK Jain. Indian Journal of Clinical Practice July 2005. <h3>Disclosure of Interest</h3> None declared
Underwater endoscopic resection of a neuroendocrine rectal tumor
Authors: Fabio Kawaguti, Joel de Oliveira, Bruno da Costa Martins, Maurício Sorbello, Felipe Retes, Ulysses Ribeiro, Fauze Maluf-Filho
Journal: Endoscopy (2015)

The endoscopic resection of rectal neuroendocrine tumors (NETs) results in good long-term outcomes [1]. Many techniques for the endoscopic resection of rectal NETs have been described, including polypectomy, endoscopic mucosal resection (EMR), and recently EMR with band ligation [2], endoscopic submucosal dissection [3], and even transanal endoscopic microsurgery [4]. Underwater endoscopic resection is a simple and inexpensive new technique that has been used for the treatment of polyps and flat lesions [5]. We present a case of rectal NET resected with an underwater technique ([Video 1]).
Elderly schizophrenic inpatients in the wake of deinstitutionalization
Authors: A B Goodman, C Siegel
Journal: American Journal of Psychiatry (1986)

The authors investigated the factors relating to the observation that in a large state hospital, there is an age-related increase in the ratio of patients with a DSM-II diagnosis of paranoid schizophrenia to those with a diagnosis of nonparanoid schizophrenia. Elderly inpatients (N = 1,518) treated over a 5-year period were studied and the hypotheses of proportionately greater numbers with late onset of paranoid conditions, longer lengths of stay for recently admitted paranoid patients, and changing diagnosis over time were tested and rejected. The data suggest that the buildup among the elderly of those diagnosed under DSM-II to have paranoid conditions is due to patients admitted well before age 54. The authors discuss the reasons for the poor prognosis of this group.
Management of Status Epilepticus
Authors: A. V. Delgado-Escueta, C. Wasterlain, D. M. Treiman, R. J. Porter
Journal: New England Journal of Medicine (1982)

IN 1824 Calmeil first described "grand mal" status epilepticus in his thesis, De l'Epilepsie.1 He had observed patients who had repeated tonic-clonic seizures and did not recover consciousness between attacks. Fifty-two years later, Bourneville referred to status epilepticus as "etat de mal" in his book published in 1876.2 The full meaning of "status epilepticus," however, was not fully appreciated until 1962, when it was defined as "epileptic seizures that are so frequently repeated or so prolonged as to create a fixed and lasting epileptic condition."3 The term was applied to continuous seizures lasting at least 30 minutes, even when . . .
Improving Safety for Hospitalized Patients
Authors: Richard Kronick, Sharon Arnold, Jeffrey Brady
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SP0155 Arthritis and Work: An Inventory of European Studies
Authors: J. Hubertsson
Journal: Annals of the Rheumatic Diseases (2015)

For patients with chronic, or long lasting, disorders symptoms often come and go with varying intensity. Living with a disease hence becomes a matter of finding a balance between the limitations of the body and the will to perform activities and participate in daily life. To be able to participate in working life an individual needs to balance his or her personal abilities and characteristics (personal factors) with factors external to the person (environmental factors). A good fit between a person and the environment might mean that a person is able to work despite remaining symptoms while an unfavourable fit might mean that the symptoms deteriorate. This session attempts to give an overview of the literature on arthritis and work. We will discuss the effect of arthritis on work participation and give a brief summary of the literature on risk factors for work disability, assessment tools and interventions. The session will include an overview of qualitative studies that explore patients own experiences of living with arthritis and remain employed or return to work. Also the effect of work and occupation on the development of disease will be discussed as knowledge about occupational risk factors for disease could contribute to an earlier detection of patients with an unfavourable fit, who might benefit from changed working conditions. <h3>Disclosure of Interest</h3> None declared
AB0192 High Expression of MIR-16 in PBMC of SLE Patients
Authors: Z. Ye, Z. Yin, H. Zeng, W. He
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a predominantly female complex autoimmune disease characterized by the production of autoantibodies against a host of nuclear antigens and immune complex deposition in organs. Recent studies have revealed the potential contribution of miRNAs in the regulation of signaling pathways and autoimmune genes in lupus, providing insights into the pathogenesis of SLE. <h3>Objectives</h3> To determine the expression of miR-16 in PBMC from Systemic lupus erythematosus (SLE) patients <h3>Methods</h3> Peripheral blood mononuclear cells (PBMC) were separated from peripheral blood of 16 SLE patients and 12 healthy individuals. Total RNAs were isolated and purified. The level of miR-16 was determined by quantitative reverse transcription PCR (qRT-PCR). U6 was used as housekeeping control. The amount of target miRNA was normalized relative to the amount of U6 (ΔCt =ΔCt<sub>miRNA</sub>-ΔCt<sub>U6</sub>). Relative expression levels were expressed as 2<sup>-Δ Ct</sup>. <h3>Results</h3> The expression level of miR-16 was significantly higher in the SLE patients than that in the healthy control group (919.87±715.45 vs 413.6 3±330.69, <i>P</i>=0.02). And it was also significantly higher in SLE active group than that in SLE stable group (540.95±350.15 vs 1298.79±803.79, <i>t=</i>-2.445, <i>P</i>&lt;0.05). The level of miR-16 was related with AnuA (<i>r</i>=0.669, <i>P</i>&lt;0.01),ESR (<i>r</i>=0.608, <i>P</i>&lt;0.05) and SLEDAI (<i>r</i>=0.530, <i>P</i>&lt;0.05). The level of miR-16 was not related with anti-dsDNA antibody, CRP, C3 and C4. <h3>Conclusions</h3> The expression of miR-16 is high in SLE patients and it is related with SLE activity. It may be a potential non-invasive biomarker for SLE diagnosis and SLE activity assessment. <h3>References</h3> Wang H, Peng W, Ouyang X, et al. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus [J]. Transl Res, 2012,160(3):198-206. Pauley KM, Satoh M, Chan AL, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients [J]. Arthritis Res Ther, 2008, 10(4):R101. Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis [J]. Arthritis Res Ther, 2010;12(3):R86. Pekarsky Y, Croce CM. Role of miR-15/16 in CLL. Cell Death Differ. 2015,22(1):6-11. <h3>Disclosure of Interest</h3> None declared
PTU-173 Feasibility study of safety and cost effectiveness of using johan forceps as endoloop pushers for laparoscopic appendicectomy
Authors: K Siddique, K Khan, T Offori
Journal: Gut (2015)

<h3>Introduction</h3> <b>Background</b>: The base of appendix can be secured using endoloops or endoscopic stapler. The authors have reported the use of Johan forceps as endoloop pushers for laparoscopic appendicectomy. <h3>Method</h3> <b>Aims</b>: To evaluate the safety and cost effectiveness of this technique. <b>Patients and methods</b>: A prospectively collected data of all patients who underwent laparoscopic appendicectomy by this technique between 2012 till 2014 was reviewed. Base of the appendix was secured using three standard extra-corporeal endoloops deployed with Johan’s forceps utilising one vicryl tie. Demographics, operative findings, post-operative complications and readmissions were recorded and analysed. <h3>Results</h3> Total number of patients was 120. There were 72 (60%) males while rest were female with an age of *24 (14–77). Grossly inflamed appendix (including perforation, localised abscess) was noted in 76% of cases. No peri-operative complications were reported. The post-op stay was *2 (1–5) days (* represents median). Complications include 7 (5.8%) wound infections which were managed conservatively. 9 patients were re-admitted due to reasons unrelated to the surgical technique. The cost of one vicryl tie was £0.5 Vs £49.80 (for 3 standard endoloops available in the market). The cost analysis showed johan assisted appendicectomy to be 99 times cheaper than the standard marketed endoloops. <h3>Conclusion</h3> Our series involving various surgeons employing the standard technique of using the Johan forceps as endoloop knot pushers shows that it is a feasible and safe technique with promising results. The technique has been practised in various hospitals and provides a cheap and safe alternative to the standard endoloops available in the market. <h3>Disclosure of interest</h3> None Declared.
Abstract 104: Sex-specific Impact Of S-nitrosoglutathione Reductase (gsnor) On Ventricular Remodeling And Function Following Myocardial Infarction In Mice.
Authors: Shathiyah Kulandavelu, Ellena Paulino, Lauro Takeuchi, Rosemeire Kanashiro-Takeuchi, Wayne Balkan, Joshua M Hare
Journal: Circulation Research (2014)

Introduction: Female hearts are less susceptible to myocardial injury following myocardial infarction (MI) and estrogen working through the nitric oxide (NO) pathway is thought to play a role. S-nitrosylation of cysteine thiols is a major signaling pathway through which NO exerts its action and mice with targeted deletion of S-nitrosoglutathione reductase (GSNOR), a denitrosylase that regulates S-nitrosylation, show increased levels of nitrosylated proteins. Male GSNOR -/- mice show a more favorable outcome after MI as compared to wild-type (WT), including reduced myocardial infarct size, improved ejection fraction and preserved left ventricular volumes. Whether female GSNOR -/- mice show gender-related cardiac protection following MI was not known and thus investigated. Methods &amp; Results: MI was induced in male and female GSNOR -/- mice and their respective controls, C57Bl/6J, at 3-5 months via left anterior descending coronary artery occlusion. Serial echocardiography was performed prior to MI and after 1- and 4-weeks post-MI to assess ejection fraction (EF) and left ventricular volume both at diastole (end-diastolic volume, EDV) and systole (end-systolic volume, ESV). Compared to WT, GSNOR -/- males showed less dilation in both EDV (98.6 ± 9.3 mm vs. 140.6 ± 7.4 mm in WT, P&lt;0.001) and ESV (73.1 ± 9.2 vs. 112.7 ± 7.3 mm in WT, P&lt;0.05) at 4 weeks post-MI. Whereas, GSNOR -/- females showed greater dilation in both EDV (162.2 ± 13 vs. 83.8 ± 12 mm in WT, P&lt;0.001) and ESV (141.8 ± 13 vs. 65.6 ± 12 mm in WT, P&lt;0.001) as compared to WT females. EF decreased (P&lt;0.001) in all groups post-MI, but at 4 weeks post-MI, it was significantly worse in GSNOR -/- females compared to GSNOR -/- males (14 ± 4% vs. 28 ± 3%, P&lt;0.05). Conclusion: GSNOR -/- females exhibit significantly lower EF and greater dilation of left ventricular volumes both at diastole and systole following MI than any of the other groups suggesting that S-nitrosylation plays an important role in gender-related cardiac protection following myocardial injury. These findings suggest the importance of taking gender into account when exploring novel therapeutic treatments for myocardial injury.
FRI0495 What Might be the Factors for Staying in Remission in JIA? Data from the German Biker Registry:
Authors: J. Peitz, I. Becker, G. Horneff
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Remission is a goal of modern treatment of JIA and can be achieved by numerous patients upon intense treatment with methotrexate, biologics or combinations. It remains unclear how many patients have sustained remission after discontinuation being off drugs. <h3>Methods</h3> In the German BIKER Registry we retrospectively analyzed the data of 3610 patients treated for juvenile idiopathic arthritis (poly or systemic) either with methotrexate or biological agents, for remission rate, flare rate after remission and whether there are factors predictive for staying in remission. Due to the small number of patients treated with adalimumab, followed in the registry only since 2012, we concentrated on 3387 patients treated either with etanercept (ETA) (1870) or methotrexate (MTX) (1517). <h3>Results</h3> In the MTX group 29.7% (451/1517) got into remission and ended treatment. In the ETA group 21.1% (395/1870) patients got into remission. Due to incomplete data for the issue we finally got 587 data sets left. In these data we found several statistically significant positive predictive factors for staying in remission (table). Non predictive factors were: antinuclear antibody positivity, CCP antibody positivity, HLA B27 carriership, age at disease onset, age at start of therapy (SOT), duration of therapy, patient VAS at SOT, number of active joints at SOT, JADAS10 at SOT or EOT, ESR at SOT or end of therapy (EOT), LOM at SOT or EOT, physicians VAS at EOT, JIA category other than systemic arthritis, NSAR at SOT or EOT, concomitant treatment with glucocorticosteroids at SOT or EOT, therapy with sulfasalazine, azathioprine, cyclosporine, NSAIDs or glucocorticoids before starting MTX or ETA therapy, ongoing MTX therapy after ending an ETA therapy. <h3>Conclusions</h3> The Biker registry primarily is a pharmacovigilance instrument with the objectives of surveillance of safety. Retrospectively we were able to find a small number of predictive factors for staying in remission off therapy. Hazard ratios of statistically significant factors however were rather low. <h3>Disclosure of Interest</h3> None declared
Effects of low-dose TRH on cognitive deficits in the ECT postictal state
Authors: A Khan, M H Mirolo, K Claypoole, J Bhang, G Cox, A Horita, G Tucker
Journal: American Journal of Psychiatry (1994)

A low dose (0.5 mg) of thyrotropin-releasing hormone (TRH), a short-acting tripeptide with known analeptic properties, was administered to eight depressed patients 5 minutes after ECT session 3 or 4 in a double-blind, placebo-controlled crossover design. After TRH infusion the patients displayed selectively better performance on a battery of neuropsychological tests than they did after placebo infusion. Further exploration with pharmacological probes to mitigate ECT postictal cognitive deficits is warranted.
The Future of Virus Studies in Tissue Culture&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: J F ENDERS
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article The Future of Virus Studies in Tissue Culture Get access John F. Enders, Ph.D. John F. Enders, Ph.D. Children's Hospital, Boston, Massachusetts Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 19, Issue 4, October 1957, Pages 735–752, https://doi.org/10.1093/jnci/19.4.735 Published: 01 October 1957 Article history Received: 28 May 1957 Published: 01 October 1957
Correction: Walnuts and Serum Lipid Profile
Authors: I Yoshikawa, I Murata, M Otsuki
Journal: Annals of Internal Medicine (2000)

Corrections17 October 2000Correction: Walnuts and Serum Lipid ProfileFREESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-8-200010170-00027 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In an article on walnuts and serum lipid profiles of hypercholesterolemic men and women (1), the last sentence of the second paragraph on page 542 should read “In addition, the difference was statistically significant in patients with baseline lipoprotein(a) levels greater than or equal to 0.3 g/L (P = 0.042) but not in those with baseline levels less than 0.3 g/L (P > 0.2).”Reference1. Zambón D, Sabaté J, Muñoz S, Campero B, Casals E, Merlos M, et al . Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women. A randomized crossover trial. Ann Intern Med. 2000;132:538-46. LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSubstituting Walnuts for Monounsaturated Fat Improves the Serum Lipid Profile of Hypercholesterolemic Men and Women Daniel Zambón , Joan Sabaté , Sonia Muñoz , Betina Campero , Elena Casals , Manuel Merlos , Juan C. Laguna , and Emilio Ros Metrics 17 October 2000Volume 133, Issue 8Page: 659KeywordsLipid profiles ePublished: 17 October 2000 Issue Published: 17 October 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Soundings: Now we are quite old
Authors: Colin Douglas
Journal: BMJ (2003)

Of the original 150 of us, about 50—most with partners—gather at a country hotel on a Friday afternoon. The sky is dull, and rain threatens. Little groups form and re-form, on the lawn and in the car park and hotel lobby, and around a pinboard with odd memorabilia: an ancient class list, typed and yellowing; the menu from our graduation dinner; a group photograph of our 20th year reunion. How young we looked then.

Who's who? It's not always clear, but name badges with photographs taken from our yearbook help, and an evening drinks reception helps a lot more. Voices have changed little, eyes least of all. But when we start talking, we are the same—if not more so.

And there is no denying we grow old: hair thins and greys, skin wrinkles, girths sag, and cartilage marches on, so that ears and noses once unremarkable loom large—impressive, or worse. Someone I have known since we were 12 has come to resemble Roald Dahl's big friendly giant.

We talk, how we talk. But now—and how different from our 10 year reunion 20 years ago—we confide rather than boast: careers are drawing to a close, and for many of us health, however subtly, is failing. And if middle age is defined as having to worry about your kids as well as your parents, quite a lot of us are middle aged in spades.

Couples are intriguing: some intuitively close over decades, clearly till death do them part; others newer, even touchy and ill at ease. Perhaps reunions and trophy wives don't mix. But an old friend, hollowed out by a harrowing bereavement when last we met, has brought his new fiancee. Wandering hand in hand by the river in morning sunlight they radiate blessedness.

Medicine has been kind to us, in many different ways and places. At our scientific session we hear some of it. Over drinks and meals we hear much more: rural practice in Devon, neonatology in Vancouver, medical bureaucracy in North Carolina, cardiology in Florida, even surgery in Edinburgh. But retirement too is much discussed. Time is passing. Talk of our 40th year reunion both helps and doesn't.

On Sunday morning we gather on the terrace for yet another group photograph. Slowly clouds hide the sun. On trees in the parkland, and among the crags above, the leaves are turning. Once more we smile for the camera. There is a nip in the air.
Would Brexit stop the flow of doctors and patients between EU countries?
Authors: Anne Gulland
Journal: BMJ (2016)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Would Brexit stop the flow of doctors and patients between EU countries? Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.